DAS-MG, Inc   Report issue

For profit Phase 2
Founded: Boston Massachusetts United States (2019)

Organization Overview

First Clinical Trial
2020
NCT04226170
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

DAS-MG, Inc

Active Ingredients

Drugs in Phase 2 Trials (2)

ondansetron (zofran) (1 trial)

pyridostigmine bromide (mestinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2